

Comparing the Published Evidence – Neox 1K

	Neox 1K	Neox 1K	TTAX01	GRAFIX	GRAFIX	GRAFIX	EPIFIX
Author/Year	Caputo 2016	Raphael 2016	Marston 2020	Frykberg 2016	Lavery 2014	Ananian 2018	Zelen 2013
Enrollment	33	32	30	31	50	38	13
Percent with exposed bone/tendon/lig	100%	100%	100%	100%	EXCLUDED	EXCLUDED	N/A BONE EXCLUDED
Percent with any infection	100%	100%	100%	EXCLUDED	EXCLUDED	EXCLUDED	EXCLUDED
Percent with osteomyelitis	100%	34%	100%	EXCLUDED	EXCLUDED	EXCLUDED	EXCLUDED
Percent with gangrene	52%		10%	EXCLUDED	EXCLUDED	EXCLUDED	EXCLUDED
Average number of applications	1.24	1.68	1.5	9	6.8	5.4	2.5
Graft application frequency	Only When Needed	Only When Needed	Only When Needed	Weekly	Weekly	Weekly	Week 1, 2, 4, 6, 8, 10
Number of in person visits	2 Visits	2 Visits	2 Visits	9 In-Person Visits	7 In-Person Visits	6 In-Person Visits	3 In-Person Visits
Allows for remote wound monitoring	YES	YES	YES	NO	NO	NO	NO
Percent complete epithelialization	78.80%	87.50%	86.20%	58.5% (N/I 2Amps 2 ET)	62%	48.40%	98.40%
Time to complete epithelialization	16 Weeks	13.8 Weeks	112 Days Confirmed Closure	9.1 Weeks	42 Days	38 Days	4.2 Weeks
Average wound size	15.6 cm ²	10.6 cm ²	7.4 cm ²	14.6 cm ²	3.41 cm ²	7.15 cm ²	NOT STATED
Wagner grade	Wagner 3 / Wagner 4	Wagner 3 / Wagner 4	Wagner 3 / Wagner 4	Wagner 2	Wagner 1	Wagner 1	Wagner 1

Caputo WJ et al. Clinical efficacy of NEOX CORD 1K in promoting healing of complex wounds with osteomyelitis. *Wound Repair Regen.* 2016 Sept 24(5): 885-893. Raphael A. 2016 The Use of Cryopreserved Umbilical Cord (cUC) for Wound Repair in Patients Suffering from Diabetic Foot Ulcers: A Retrospective Analysis, *J Wound Care.* 2016 Jul;25 Suppl 7:S10-7 Marston W et al. One-year safety, healing and amputation rates of Wagner 3-4 diabetic foot ulcers treated with cryopreserved umbilical cord (TTAX01). *Wound Repair Regen.* 2020; 28:526-31. Frykberg RG et al. A prospective, multicentre, open-label, single-arm clinical trial for treatment of chronic complex diabetic foot wounds with exposed tendon and/or bone: positive clinical outcomes of viable cryopreserved human placental membrane., *Int Wound J.* 2016 Aug 3. Lavery, L.A et al. The efficacy and safety of Grafix® for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial. *Int Wound J.* 2014; 11: 554-560. Ananian CE et al. A multicenter, randomized, single-blind trial comparing the efficacy of viable cryopreserved placental membrane to human fibroblast-derived dermal substitute for the treatment of chronic diabetic foot ulcers. *Wound Repair Regen.* 2018 May;26(3):274-283. Zelen CM et al. A prospective randomised comparative parallel study of amniotic membrane wound graft in the management of diabetic foot ulcers. *Int Wound J.* 2013 Oct;10(5):502-7.